Department of Medicine and Health Science "V. Tiberio", University of Molise, 86100 Campobasso, Italy.
Department of Science and Technology (DST), University of Sannio, 82100 Benevento, Italy.
Int J Mol Sci. 2019 Jul 10;20(14):3382. doi: 10.3390/ijms20143382.
Kv7.2 subunits encoded by the gene provide a major contribution to the M-current (I), a voltage-gated K current crucially involved in the regulation of neuronal excitability. Heterozygous missense variants in Kv7.2 are responsible for epileptic diseases characterized by highly heterogeneous genetic transmission and clinical severity, ranging from autosomal-dominant Benign Familial Neonatal Seizures (BFNS) to sporadic cases of severe epileptic and developmental encephalopathy (DEE). Here, we describe a patient with neonatal onset DEE, carrying a previously undescribed heterozygous c.418G > C, p.Glu140Gln (E140Q) variant. Patch-clamp recordings in CHO cells expressing the E140Q mutation reveal dramatic loss of function (LoF) effects. Multistate structural modelling suggested that the E140Q substitution impeded an intrasubunit electrostatic interaction occurring between the E140 side chain in S and the arginine at position 210 in S (R210); this interaction is critically involved in stabilizing the activated configuration of the voltage-sensing domain (VSD) of Kv7.2. Functional results from coupled charge reversal or disulfide trapping experiments supported such a hypothesis. Finally, retigabine restored mutation-induced functional changes, reinforcing the rationale for the clinical use of Kv7 activators as personalized therapy for DEE-affected patients carrying Kv7.2 LoF mutations.
Kv7.2 亚基由 基因编码,对 M 电流(I)有主要贡献,M 电流是一种电压门控 K 电流,对神经元兴奋性的调节至关重要。Kv7.2 的杂合错义变体负责癫痫疾病,其遗传传递和临床严重程度高度异质,从常染色体显性良性家族性新生儿癫痫(BFNS)到散发性严重癫痫和发育性脑病(DEE)病例不等。在这里,我们描述了一名新生儿期 DEE 患者,携带先前未描述的杂合子 c.418G > C,p.Glu140Gln(E140Q)变体。在表达 E140Q 突变的 CHO 细胞中的膜片钳记录显示出明显的功能丧失(LoF)效应。多态结构建模表明,E140Q 取代阻止了 S 中 E140 侧链与 S 中位置 210 的精氨酸之间发生的亚基内静电相互作用(R210);这种相互作用对于稳定 Kv7.2 的电压传感域(VSD)的激活构象至关重要。来自偶联电荷反转或二硫键捕获实验的功能结果支持了这样的假设。最后,瑞替加滨恢复了突变诱导的功能变化,这强化了 Kv7 激活剂作为携带 Kv7.2 LoF 突变的 DEE 患者个体化治疗的临床应用的合理性。